Acasti Pharma Inc. Daily Stock Analysis

Daily Stock Analysis, ACST, Acasti Pharma Inc, priceseries

Acasti Pharma Inc. Daily Stock Analysis
Stock Information
Open
1.05
Close
1.07
High
1.09
Low
1.04
Previous Close
1.06
Daily Price Gain
0.01
YTD High
1.59
YTD High Date
Jan 5, 2022
YTD Low
1.00
YTD Low Date
Feb 24, 2022
YTD Price Change
-0.31
YTD Gain
-22.46%
52 Week High
6.50
52 Week High Date
Mar 15, 2021
52 Week Low
1.00
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-3.93
52 Week Gain
-78.60%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 23. 2017
11.60
Jan 24. 2017
12.20
1 Trading Days
5.17%
Link
LONG
Feb 17. 2017
10.64
Feb 21. 2017
11.24
1 Trading Days
5.64%
Link
LONG
Sep 19. 2018
4.50
Oct 10. 2018
8.97
15 Trading Days
99.30%
Link
LONG
Jan 7. 2019
7.36
Jan 24. 2019
8.29
12 Trading Days
12.58%
Link
LONG
Jun 14. 2019
7.20
Jul 17. 2019
11.00
22 Trading Days
52.76%
Link
LONG
Jul 18. 2019
12.64
Aug 5. 2019
17.83
12 Trading Days
41.08%
Link
LONG
Mar 24. 2020
2.64
Apr 1. 2020
2.78
6 Trading Days
5.48%
Link
LONG
Apr 8. 2020
2.97
May 14. 2020
5.00
25 Trading Days
68.33%
Link
LONG
Jun 2. 2020
5.18
Jun 11. 2020
5.72
7 Trading Days
10.39%
Link
LONG
Jul 6. 2020
4.88
Jul 14. 2020
5.14
6 Trading Days
5.33%
Link
LONG
Jan 4. 2021
3.16
Jan 27. 2021
5.23
16 Trading Days
65.65%
Link
LONG
Feb 3. 2021
5.65
Feb 18. 2021
7.40
10 Trading Days
30.90%
Link
LONG
May 18. 2021
3.64
Jun 15. 2021
4.24
19 Trading Days
16.39%
Link
LONG
Aug 2. 2021
3.88
Aug 4. 2021
4.20
2 Trading Days
8.11%
Link
Company Information
Stock Symbol
ACST
Exchange
NasdaqCM
Company URL
http://www.acastipharma.com
Company Phone
(450) 687-2262
CEO
Janelle D'Alvise
Headquarters
Quebec
Business Address
545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL, CANADA H7T 0A3
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001444192
About

Acasti Pharma, Inc. engages in the research, development, and commercialization of krill oil-based forms of omega-3 phospholipid therapies. It seeks to treat certain cardiometabolic disorders such as abnormalities in blood lipids, also known as dyslipidemia. It sproduct candidate, CaPre, is being developed to treat severe hypertriglyceridemia. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.

Description

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of various cardiometabolic disorders primarily abnormalities in blood lipids. The company offers Onemia, a medical food product for the dietary management of omega-3 phospholipids deficiency, and related abnormal lipid profiles and cardiometabolic disorders. It also develops CaPre, a prescription drug candidate for the prevention and treatment of cardiometabolic disorders, such as hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading